Introduction
============

Glaucoma is the second leading cause of preventable blindness worldwide. In 2010 worldwide approximately 60.5 million people are suffering primary open angle glaucoma (POAG) and angle closure glaucoma (ACG). This number is estimated to increase to 79.6 million by 2020.[@b1-opth-5-623] Increased intraocular pressure (IOP) is considered to be the most important but modifiable risk factor.[@b2-opth-5-623]--[@b4-opth-5-623] Worldwide, prostaglandin analogs (PGAs) have become the major therapeutic class for medical treatment of glaucoma because of their efficacy and generally well tolerated systemic safety profile.[@b5-opth-5-623] Tafluprost is a novel PGA that has been approved for ophthalmic use in a number of markets worldwide. The drug is currently marketed under the brand names: Taflotan[^+^](#fn1-opth-5-623){ref-type="fn"} and Taflotan[^+^](#fn1-opth-5-623){ref-type="fn"} sine and Tapros[^†^](#fn2-opth-5-623){ref-type="fn"}, by Santen Pharmaceutical Co. LTD, Japan and as Saflutan[^††^](#fn3-opth-5-623){ref-type="fn"} by Merck & Co, Inc. Tafluprost is highly selective for the prostaglandin FP-receptor.[@b6-opth-5-623],[@b7-opth-5-623] PGAs including Tafluprost have a strong, sustained and stable IOP-lowering effect with few systemic side effects. In clinical studies the drug lowered IOP effectively and was generally well tolerated.[@b8-opth-5-623]--[@b10-opth-5-623] Unfortunately, PGAs may induce local adverse events, including conjunctival hyperemia, iris and periocular skin pigmentation and eyelash growth.[@b9-opth-5-623],[@b11-opth-5-623] Hyperemia is the most common local adverse reaction to PGAs. Furthermore this local adverse event seems to be dose-dependent.[@b12-opth-5-623],[@b13-opth-5-623] Tafluprost is commercially available in a low concentration of the active ingredient of 0.0015%. Furthermore, among all widely used PGAs, tafluprost is the first and only preparation that is available in a preservative-free formulation. This may be important because special attention has been paid to the cytotoxicity of benzalkonium chloride (BAK), which is widely used in glaucoma preparations as a preservative. BAK is pro-apoptotic, pro-inflammatory and causes a damage of the tear film by emulsification of the lipid layer.[@b14-opth-5-623]--[@b16-opth-5-623] A complete loss of conjunctival goblet cells was also reported in different studies.[@b17-opth-5-623],[@b18-opth-5-623] Other clinical studies demonstrate major differences with respect to subjective symptoms, local tolerability and objective clinical signs after the use of preserved and preservative-free glaucoma medications.[@b19-opth-5-623]--[@b21-opth-5-623]

The overall results of this observational study have already been published.[@b22-opth-5-623] The purpose of this post-hoc analysis was to assess efficacy, tolerability and safety of preservative-free tafluprost in a subset of patients that were switched from a prior monotherapy with preserved PGAs to a monotherapy with preservative-free tafluprost 0.0015% in a routine clinical setting.

Material and methods
====================

Study design
------------

This was a non-interventional, observational, open-label, non-randomized multi-center study, that was conducted between October 2008 and April 2009 in 75 centers in Germany. The study treatment was based on the decision of the physician only, regardless of study participation and treatment use. German law does not require informed consent for this type of non-interventional observational study. Patients previously diagnosed with glaucoma or ocular hypertension who required a change of medication, an add-on therapy or who were naïve to medical treatment were followed for 12 weeks after changing medication to, or initiation of medical therapy with, the preservative-free formulation of tafluprost 0.0015% once-daily. The primary objective of this study was to evaluate the change of mean IOP from baseline to final visit. Secondary objectives were to evaluate the change of clinical signs and subjective symptoms from baseline to final visit.

Patients
--------

The study included patients with different types of glaucoma and ocular hypertension, primarily those with tolerability issues and insufficient IOP control with prior medical therapy.

Measurements and statistical analysis
-------------------------------------

Using an internet- based standardized data collection format, participating ophthalmologists provided anonymous patient data. The switch was done at the physician's discretion, and their reasons for recommending the new medication were collected by providing multiple categories (ocular signs and symptoms, lowering of IOP not sufficient, contraindication, systemic intolerability, progression of glaucomatous defects, tachyphylaxis, others). Demographics, information about prior treatments and IOP readings were recorded. Due to the observational character of the study no instructions were made to the study participants concerning the time of IOP measurements during the day and the time-point to administer the medication during the day (evening or morning dose). The presence of subjective symptoms (burning, foreign body sensation, itching, irritation, stinging, tearing, dryness) and clinical signs (hyperemia, corneal staining, blepharitis) were recorded subjectively by the physician using a 4-point scale (none, mild, moderate, severe) at the initial visit. Symptoms at final visit (week 12) were compared to baseline by the patient, and clinical signs were recorded by the physician. IOP measurements were made using Goldman applanation tonometry for each eye, at the slitlamp in a sitting position, at baseline (run-in on prior treatment or start of medical therapy), 4 to 6 weeks and 12 weeks after changing treatment to preservative-free tafluprost 0.0015%. Glaucomatous damage was defined by using automatic perimetry, ophthalmoscopy and/or optic nerve head/fundus imaging techniques. Paired *t*-tests were conducted to compare IOP values at baseline to IOP values after treatment with tafluprost 0.0015%. Bowker's test of symmetry was used for statistical evaluation of changes of clinical signs (hyperemia). All adverse reactions were recorded by the physicians.

Results
=======

Patient demographics and prior therapy
--------------------------------------

In 118 patients, medical treatment was changed from a prior PGA monotherapy at baseline to preservative-free tafluprost 0.0015%. The results from this subset of patients are reported here. The majority of patients in the PGA-subgroup were female (n = 82; 69.5%). Primary open angle glaucoma (POAG) was the most common diagnosis (n = 93; 78.8%) followed by ocular hypertension (OH) (n = 14; 11.9%), normal tension glaucoma (NTG) (n = 10; 8.5%) and exfoliative glaucoma (PEX) (n = 1; 0.8%). At baseline prior to change of medication to a monotherapy with preservative-free tafluprost, 68 patients (57.6%) were treated with latanoprost, 32 patients (27.1%) with travoprost and 18 patients (15.3%) with bimatoprost ([Table 1](#t1-opth-5-623){ref-type="table"}).

Reasons for changing medication
-------------------------------

Subjective symptoms and clinical signs were the most important reasons for changing medical therapy (n = 72 patients; 61.0%). Prior medication was changed for 24 patients (20.3%) due to efficacy reasons ([Figure 1](#f1-opth-5-623){ref-type="fig"}).

Effect on IOP
-------------

Overall mean IOP (±SD) was 16.2 ± 4.3 mm Hg (95% CI: 0.55) at treated baseline. Four to 6 weeks after changing medication, overall mean IOP was reduced to 15.0 ± 3.2 mm Hg (95% CI: 0.43), and after 12 weeks to 14.8 ± 3.2 mm Hg (95% CI: 0.43) ([Figure 2](#f2-opth-5-623){ref-type="fig"}). This IOP reduction is equivalent to 8.4% and 8.6% from treated baseline, respectively. At both 4 to 6 weeks and 12 weeks, overall treated IOP values were significantly lower than baseline values (*P* \< 0.001). A reduction of mean IOP was also achieved for all different PGA compounds: In patients with prior latanoprost monotherapy (n = 68) mean IOP at baseline (±SD) was reduced from 16.2 ± 4.6 mm Hg (95% CI: 0.77) to 14.8 ± 3.1 mm Hg at final visit (95% CI: 0.54; *P* \< 0.001); in patients with prior travoprost monotherapy (n = 32) from 16.2 ± 4.3 mm Hg (95% CI: 1.05) to 14.9 ± 3.3 mm Hg (95% CI: 0.91; *P* \< 0.05); and in patients with prior bimatoprost monotherapy (n = 18) from 16.4 ± 3.5 mm Hg (95% CI: 1.14) to 15.0 ± 3.3 mm Hg (95% CI: 1.14; *P* = 0.252). In all patients with prior PGA monotherapy, IOP at final visit compared to baseline IOP was lower in 109 eyes (46.2%), equal in 51 eyes (21.6%) and higher in 76 eyes (32.2%) ([Figure 3](#f3-opth-5-623){ref-type="fig"}). In all patients with prior PGA monotherapy, preservative-free tafluprost 0.0015% provided IOP-values of ≤18 mm Hg for 83.1%, ≤16 mm Hg for 68.6%, ≤14 mm Hg for 51.7% and ≤12 mm Hg for 28.0% of all eyes. In the subset of patients (n = 24) who were switched from prior PGA monotherapy to preservative-free tafluprost due to efficacy reasons mean IOP was lowered significantly by −3.9 mm Hg (*P* \< 0.001) compared to baseline. Individual IOP's in those patients were lower at final visit compared to baseline in 28 eyes (58.2%), stayed the same in 12 eyes (25.0%) and were higher compared to baseline in 6 eyes (16.7%). In contrast IOP in two subsets of patients switched due to ocular signs (n = 31) and due to subjective symptoms (n = 41) a smaller effect on IOP reduction was observed ([Table 2](#t2-opth-5-623){ref-type="table"}).

Clinical signs and ocular symptoms
----------------------------------

Clinical signs also improved by the final examination (12 weeks after changing medical treatment). The frequency and severity of hyperemia was reduced over the 3 month treatment period. In all patients with prior PGA monotherapy the percentage of patients without any signs of hyperemia increased from 35.6% (n = 42) at baseline prior to changing medication to 87.7% (n = 93) (*P* \< 0.001). In addition, no severe hyperemia was observed at final visit 12 weeks after changing medication to preservative-free tafluprost ([Figure 4](#f4-opth-5-623){ref-type="fig"}). At baseline prior to change of medication, burning, foreign body sensation, itching, irritation, stinging, tearing and dryness were reported by 55.9%, 36.5%, 33.1%, 58.5%, 16.9%, 27.1% and 21.2% of patients respectively. These subjective symptoms improved by the final examination compared to baseline ([Figure 5](#f5-opth-5-623){ref-type="fig"}).

Safety and terminations of treatment
------------------------------------

Few adverse reactions were associated with the use of preservative-free tafluprost. One hundred and six patients completed the study and continued with a monotherapy with preservative-free tafluprost. Three patients (2.5%) terminated the treatment due to a lack of efficacy, 2 patients due to conjunctival hyperemia (1.7%), 3 patients (2.5%) due to handling issues and preference, 3 patients (2.5%) due to tolerability issues (burning, hyperemia, stinging, dryness) and 1 patient (0.8%) due to subjective malaise.

Discussion
==========

The results of this non-interventional, open-label, multi-centre observational study demonstrate that preservative-free tafluprost can achieve good IOP control in patients switched from a prior PGA monotherapy due to poor IOP control and/or tolerability issues. After change of medication mean IOP decreased significantly until final visit by 1.4 mm Hg (8.7%). There were two main reasons for switching therapy from prior PGA monotherapy to preservative-free tafluprost: Ocular symptoms and clinical signs like hyperemia accounted for 61.0% and a lack of efficacy of prior medication for 20.3% of changes of treatment. This may explain why the mean (treated) IOP at baseline was relatively low, 16.2 ± 4.3 mm Hg. Interestingly, regardless of low mean baseline IOP, lower IOP-values were achieved 12 weeks after changing medication from prior PGA monotherapy in a high proportion of patients: IOP was lower compared to baseline IOP in 109 eyes (46.2%), remained at the same level in 51 eyes (21.6%) and was higher in 76 eyes (32.2%). In patients switched due to a lack of efficacy of prior PGA monotherapy significant lower mean IOP-values were achieved (−3.9 mm Hg versus treated baseline; *P* \< 0.001). Lower individual IOP's were achieved in 58.2% of all eyes of these patients. These findings suggest that it may be worthwhile to consider a change of medication to preservative-free tafluprost for patients treated with preserved PGAs with insufficient IOP response. The efficacy of preservative-free tafluprost was compared to other prostaglandins in various studies.[@b9-opth-5-623],[@b23-opth-5-623]--[@b26-opth-5-623] In a study comparing efficacy and safety of tafluprost 0.0015% and latanoprost 0.005%, Uusitalo et al[@b9-opth-5-623] found a decrease of mean IOP versus. baseline of −7.1 mm Hg in the tafluprost treatment group (−29.1%) compared with −7.7 mm Hg (−32.2%) in the latanoprost treatment group. Non-inferiority was shown in this study with ANOVA and almost reached with ANCOVA. Compared to these results our study design was different: Firstly, patients with prior PGA treatment were switched to preservative-free tafluprost without any washout-period. Secondly, a high proportion of patients were switched to preservative-free tafluprost due to tolerability (subjective symptoms and/or clinical signs such as hyperemia) and/or efficacy issues. The study design of the present study may therefore better reflect the treatment algorithms in day to day practice and also explain the additional decrease in mean IOP seen in this study. In a phase I study with formulations containing 0.0025 and 0.005% tafluprost, IOP was lowered effectively with both concentrations of tafluprost.[@b24-opth-5-623] The higher concentration of tafluprost provided a significantly greater IOP reduction compared to latanoprost for most time-points. However, this study was performed in healthy male volunteers over a relatively short period of time of 7 days. Another study comparing efficacy and tolerability of tafluprost and travoprost found a difference in 12-hour mean IOP of 0.6 mm Hg in favor of travoprost.[@b25-opth-5-623] However, the formulation of tafluprost used in this study was not detailed. Due to the double-blind character of this study it might be assumed that the preserved-formulation of tafluprost was used, which might explain the different findings, especially related to the development of clinical signs such as hyperemia compared to the present study. The presence of the preservative BAK seems to have no influence on the efficacy of tafluprost: in a study comparing the effect of a BAK-preserved and a preservative-free formulation of tafluprost, the formulations did not differ significantly in their IOP lowering effect.[@b26-opth-5-623] Even a small change in IOP seems to be important with respect to visual field and optic nerve preservation: every 1 mm Hg was found to be equivalent to an increased risk of glaucoma progression of 10% to 19%.[@b3-opth-5-623],[@b27-opth-5-623]

Local tolerability and clinical signs are other important factors in patients with chronic diseases such as glaucoma. Two aspects are important in this context: firstly, a large body of evidence exists showing that the long-term use of topical drugs containing BAK as a preservative may induce changes in the ocular surface, tear film instability, epithelial apoptosis, conjunctival inflammation and loss of goblet cells.[@b14-opth-5-623]--[@b18-opth-5-623] Secondly, there is evidence that the prevalence of ocular surface disorders is high in glaucoma patients: in a study by Leung 59% of patients with open-angle glaucoma or ocular hypertension reported dry eye symptoms in at least 1 eye.[@b28-opth-5-623] In another study by Erb, dry eye syndrome was diagnosed in 52.6% of glaucoma patients.[@b29-opth-5-623] In both studies, the occurrence of dry eye syndrome increased with the number of preservative-containing antiglaucoma drugs used.

After switching from preserved PGA monotherapy to preservative-free tafluprost, subjective symptoms and clinical signs such as hyperemia improved significantly (*P* \< 0.001) in most patients. Consistent with previous reports our results confirm that patients with irritation of the ocular surface, subjective symptoms and clinical changes of the eye surface, such as hyperemia, may benefit from a change of medication to the preservative-free formulation of tafluprost.[@b30-opth-5-623] During the course of this observational study hyperemia which was present in a high proportion of patients at baseline decreased significantly: No patient showed a severe hyperemia at the end of the study-period. In 87.7% of patients with prior PGA-monotherapy treatment no conjunctival hyperemia was present after 12 weeks. Regarding local tolerability of glaucoma medications, clinical studies show that a high proportion of glaucoma patients develop symptoms like burning and stinging, foreign body sensation, dry eye and irritation of the ocular surface. Consistent with prior reports[@b19-opth-5-623],[@b20-opth-5-623] that these symptoms were reported significantly less often in patients receiving preservative-free preparations, subjective symptoms improved until final visit in this subset of patients treated with prior PGA monotherapy. Preservative-free tafluprost was generally well tolerated and safe: 106 patients (89.8%) remained on a monotherapy with preservative-free tafluprost after the 12 weeks of treatment.

This observational study is limited by its open-label design. Due to its observational nature, the study did not reveal any causal relationships. The observed IOP reduction after switching might be ascribed not only to the improvement of subjective symptoms and clinical signs and thus a better compliance, but also to the patient population at baseline itself. Also, regression to the mean cannot be ruled out in the current study design since a control group was not used. Further studies with higher numbers of patients are necessary to determine what aspects of preservative-free therapy with tafluprost account for the observed treatment effects.

Conclusion
==========

In this observational study, preservative-free tafluprost 0.0015% was effective and generally well tolerated in patients with prior PGA monotherapy. Preservative-free tafluprost provided further IOP reduction in patients with poor IOP control and/or poor tolerance of their medication prior to tafluprost use. Mean IOP decreased slightly after change of medication to preservative-free tafluprost. In patients with prior latanoprost monotherapy (n = 68) mean IOP at baseline (±SD) was reduced from 16.2 ± 4.6 mm Hg to 14.8 ± 3.1 mm Hg at final visit (*P* \< 0.001); in patients with prior travoprost monotherapy (n = 32) from 16.2 ± 4.3 mm Hg to 14.9 ± 3.3 mm Hg (*P* \< 0.05); and in patients with prior bimatoprost monotherapy (n = 18) from 16.4 ± 3.5 mm Hg to 15.0 ± 3.3 mm Hg (*P* = 0.252). Change of medication to preservative-free tafluprost may be beneficial especially for patients with objective clinical signs and subjective symptoms of ocular surface disease: conjunctival hyperemia which was present at baseline in 64.4% of patients treated with a PGA monotherapy decreased significantly (*P* \< 0.001) during the 12 week treatment period and was found in only 12.3% of patients at final visit. Our data further suggest that a change of medical therapy to preservative-free tafluprost in patients with prior preserved PGA monotherapy may be especially beneficial for patients with subjective ocular symptoms and/or clinical signs and also for patients who are not responding adequately to a prior PGA monotherapy treatment regimen.
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![Mean IOP (±SD) in all patients (n = 118) treated with prior PGA monotherapy and for the different PGA compounds.\
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![IOP in all individual patients (n = 118; 236 eyes) treated with prior PGA monotherapy at baseline versus final visit after change of medication to a monotherapy with preservative-free tafluprost 0.0015%.\
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![Development of conjunctival hyperemia after change of medication from prior PGA monotherapy to a monotherapy with preservative-free tafluprost 0.0015%.\
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![Development of subjective symptoms after change of medication from prior PGA monotherapy to a monotherapy with preservative-free tafluprost 0.0015%.\
**Abbreviation:** PGA, prostaglandin analog.](opth-5-623f5){#f5-opth-5-623}

###### 

Patient demographics, diagnoses and medical treatment at baseline (n = 118)

  --------------------------------------- -----------------
  Age (mean \[range\]) (years)            63.6 \[32--92\]
  Gender (male/female)                    36/82
  Diagnoses                               
  -- Ocular hypertension                  14 (11.9%)
  -- Primary open angle glaucoma          93 (78.8%)
  -- Normal tension glaucoma              10 (8.5%)
  -- Exfoliative glaucoma                 1 (0.8%)
  Glaucoma since years (mean \[range\])   6.7 \[1--22\]
  Prior PGA treatment (monotherapy)       
  -- Latanoprost                          68 (57.6%)
  -- Travoprost                           32 (27.1%)
  -- Bimatoprost                          18 (15.3%)
  --------------------------------------- -----------------

**Abbreviation:** PGA, prostaglandin analog.

###### 

Differences in mean IOP between baseline (prior PGA therapy) and final visit 12 weeks after changing medication to preservative-free tafluprost stratified by reasons for change of medication

  **Reason for changing medication**                                   **Number of patients (baseline visit)**   Δ**IOP (mm Hg)**   ***P*-value[\*\*](#tfn3-opth-5-623){ref-type="table-fn"}**
  -------------------------------------------------------------------- ----------------------------------------- ------------------ ------------------------------------------------------------
  IOP lowering effect not sufficient or target pressure not achieved   24                                        --3.9              \<0.001
  Ocular signs                                                         31                                        --1.4              0.009
  Subjective symptoms                                                  41                                        --0.1              0.761

**Note:**

LOCF-analysis, t-test for paired samples.

**Abbreviations:** ΔIOP, IOP at final visit minus IOP at baseline; IOP, intraocular pressure; PGA, prostaglandin analog.
